Equities

Genus PLC

GNS:LSE

Genus PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,736.00
  • Today's Change32.00 / 1.88%
  • Shares traded40.00k
  • 1 Year change-36.04%
  • Beta0.2551
Data delayed at least 20 minutes, as of Apr 26 2024 18:08 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Genus PLC had net income fall -18.58% from 40.90m to 33.30m despite a 16.23% increase in revenues from 593.40m to 689.70m.
Gross margin--
Net profit margin4.47%
Operating margin7.00%
Return on assets2.90%
Return on equity5.79%
Return on investment3.30%
More ▼

Cash flow in GBPView more

In 2023, cash reserves at Genus PLC fell by 2.50m. However, the company earned 50.40m from its operations for a Cash Flow Margin of 7.31%. In addition the company used 30.90m on investing activities and also paid 18.20m in financing cash flows.
Cash flow per share1.17
Price/Cash flow per share14.87
Book value per share8.71
Tangible book value per share5.99
More ▼

Balance sheet in GBPView more

Genus PLC has a Debt to Total Capital ratio of 33.77%, a lower figure than the previous year's 41.45%.
Current ratio2.15
Quick ratio1.40
Total debt/total equity0.5082
Total debt/total capital0.3377
More ▼

Growth rates in GBP

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -19.33%. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is the highest in its industry.
Div yield(5 year avg)1.05%
Div growth rate (5 year)4.24%
Payout ratio (TTM)62.87%
EPS growth(5 years)25.17
EPS (TTM) vs
TTM 1 year ago		-3.61
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.